Who
Mark Strobeck
President and CEO
Company insider
Files Form 4 as: President and CEO, Rockwell Medical; Director, Windtree Therapeutics; EVP & Chief Operating Officer, Assertio Holdings; Chief Operating Officer, Zyla Life Sciences.
In numbers
- Trades disclosed
- 74
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $997K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 11 Feb 2014
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Sold | $8,4201,000 at $8.42 | filing |
| 1 Jul 2026filed 6 Jul 2026 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 Jul 2026filed 6 Jul 2026 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 14 Mar 2026filed 16 Mar 2026 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code F | $6,6007,333 at $0.90 | filing |
| 14 Mar 2026filed 16 Mar 2026 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code F | $6,6007,333 at $0.90 | filing |
| 1 Oct 2025filed 1 Oct 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Sold | $8,2426,926 at $1.19 | filing |
| 1 Jul 2025filed 3 Jul 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Sold | $5,6796,926 at $0.82 | filing |
| 1 Jul 2025filed 2 Jul 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Sold | $5,6796,926 at $0.82 | filing |
| 20 May 2025filed 17 Apr 2026 | RMTI Rockwell Medicaloption or derivative · Biotechnology | SEC FORM 4 Code A | —352,000 at $0.00 | filing |
| 20 May 2025filed 17 Apr 2026 | RMTI Rockwell Medicaloption or derivative · Biotechnology | SEC FORM 4 Code A | —352,000 at $0.00 | filing |
| 20 May 2025filed 21 May 2025 | RMTI Rockwell Medicaloption or derivative · Biotechnology | SEC FORM 4 Code A | —308,000 at $0.00 | filing |
| 20 May 2025filed 21 May 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Sold | $7,4806,926 at $1.08 | filing |
| 17 Mar 2025filed 18 Mar 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code F | $11K6,101 at $1.77 | filing |
| 14 Mar 2025filed 18 Mar 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code F | $12K7,333 at $1.70 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Sold | $4,4562,163 at $2.06 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Sold | $7,9812,163 at $3.69 | filing |
| 17 Mar 2024filed 19 Mar 2024 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code F | $8,5416,101 at $1.40 | filing |
| 14 Mar 2024filed 15 Mar 2024 | RMTI Rockwell Medicaloption or derivative · Biotechnology | SEC FORM 4 Code A | —141,560 at $0.00 | filing |
| 14 Mar 2024filed 15 Mar 2024 | RMTI Rockwell MedicalBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
News
Rockwell Medical (NASDAQ:RMTI) Shares Cross Above Two Hundred Day Moving Average After Analyst DowngradeRMTI · tickerreport.com · 17 Oct 2026
0 headlines in the last 90 days name Mark Strobeck; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.